Pineda-Moncusí M, et al. - Women diagnosed with breast cancer between 2006 and 2015 and treated with tamoxifen or aromatase inhibitors (n = 36,472) were scaled according to low (without osteoporosis diagnosis nor bisphosphonates exposure) or high (with osteoporosis and/or treated with bisphosphonates) fracture risk in order to assess the fracture risk in breast cancer individuals who were receiving aromatase inhibitors, in comparison with tamoxifen users, and to evaluate the efficiency of oral bisphosphonates in decreasing fracture risk. During aromatase inhibitor treatment, fracture risk in postmenopausal women, in real-life conditions, was > 40% in comparison with tamoxifen, authenticating former randomized controlled trial outcomes. In high-risk individuals, bisphosphonate users vs non-bisphosphonate-users had lower notable fracture incidence during aromatase inhibitor therapy. Furthermore, in aromatase inhibitor individuals, monitoring fracture risk and related risk factors are suggestive.